Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples. No patients will be enrolled in this study. Data will be collected for approximately 6 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| INCa molecular genetics laboratory "in-house" methods | BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods | ||
| Cobas 4800 Mutation Test | BRAF V600 mutations were analysed using Cobas 4800 mutation test |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories | BRAF V600 mutation status was determined by INCa molecular laboratories "in-house" methods and Cobas 4800 BRAF V600 mutation test. Samples were analysed as V600 mutation, No V600 mutation and Non evaluable. Additionally, the type of V600 mutation (E, K, R, D, E2, other V600 mutation, not specified) was also evaluated only by INCa molecular laboratory "in-house" method. | Up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Tumor Sample Characteristics-Type of Tumor Sample | The type of tumor sample used for evaluation of BRAF V600 mutation whether it was a biopsy or surgical specimen were reported | Up to 6 months |
| Tumor Sample Characteristics - Source of Tumor Sample |
Not provided
Inclusion Criteria:
No patients are enrolled. Use of tumor samples only.
Exclusion Criteria:
No patients are enrolled. Use of tumor samples only.
Not provided
Not provided
Not provided
Not provided
No patients are enrolled in this study. Use of melanoma tumor samples.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boulogne-Billancourt | 92104 | France | ||||
A total 420 melanoma tumor samples were analysed in 12 platform laboratories in France. The paraffin-embedded tumour samples were taken from biopsy or surgical specimen from the internal or external pathology laboratory.
The study was conducted from 12 December 2012 to 03 April 2013 which evaluated 420 samples for detection of BRAF V600 mutation in France laboratories.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Melanoma Tumor Sample With BRAF V600 Mutation | BRAF V600 mutations were analysed in melanoma tumor samples using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods and Cobas 4800 mutation test |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Biological samples were analysed rather than samples
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Melanoma Tumor Sample With BRAF V600 Mutation | BRAF V600 mutations were analysed in melanoma tumor samples using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods and Cobas 4800 mutation test |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories | BRAF V600 mutation status was determined by INCa molecular laboratories "in-house" methods and Cobas 4800 BRAF V600 mutation test. Samples were analysed as V600 mutation, No V600 mutation and Non evaluable. Additionally, the type of V600 mutation (E, K, R, D, E2, other V600 mutation, not specified) was also evaluated only by INCa molecular laboratory "in-house" method. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. n = number of samples with BRAF V600 mutation by "in-house method". | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
Not provided
As the samples were used instead of participants for analysis there were no serious or non-serious adverse events reported.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | INCa Molecular Genetics Laboratory "in House" Methods | BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using in-house methods |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Roche Trial Information Hotline | F. Hoffmann-La Roche AG | +41 61 6878333 | global.trial_information@roche.com |
Not provided
| ID | Term |
|---|---|
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
The source of tumor sample for BRAF V600 mutation detection whether taken from internal or external pathology laboratory were reported
| Up to 6 months |
| Type of Pathology Laboratory Performing the Fixation or Embedding-Pre-analytical Method | The external or internal pathology laboratories involved in the process of fixation or embedding of the tumor sample was evaluated. | Up to 6 months |
| Time From Sampling to Fixation- Pre-analytical Method | Time taken from the sampling to the fixation of the tumor sample was reported in range of 0-2 hours, 2-6 hours, >6 hours and unknown. Number of samples falling in each of the class were reported. | Up to 6 months |
| Type of Fixative Used- Pre-analytical Method | The different types of fixative Excell, formol, alcohol formol acetic acid and other, used to fix the tumor samples were reported. | Up to 6 months |
| Fixation Duration by Pre-analytical Method | Fixation duration is defined as the amount of time required in hours for the fixation of a samples. The fixation duration was categorized as <6 hours, 6-24 hours and >24 hours and unknown. Number of samples falling in each category were reported | Up to 6 months |
| Slice Thickness by Pre-analytical Method | Slice thickness of all the tumour samples was measured. The slice thickness was measured in micrometer. | Up to 6 months |
| Dewaxing by Pre-analytical Method | Dewaxing is a method to recover the DNA from samples. Dewaxing information was collected as "Yes, No or Missing" | Up to 6 Months |
| Necrosis Percentage Determination by Pre-analytical Method | The percentage of necrosis defined as the death of one or more cells in the analysed zone was reported. | Up to 6 months |
| Percentage of Tumor Cells by Pre-analytical Method | The percentage of tumor cells in the given tumor sample were reported. | Up to 6 months |
| Tumor Samples With Presence of Melanin by Pre-analytical Method | The tumor samples with presence of melanin were categorized as Important, Few, Medium and Absent. | Up to 6 months |
| DNA Extraction - Extraction Method by Pre-analytical Method | This method assessed DNA from the tumor samples was extracted by Automated method or Manual method. | Up to 6 months |
| Median DNA Elution Volume by Pre-analytical Method | Median DNA elution volume microliters [mcl] was reported. | Up to 6 months |
| Mean DNA Concentration by Pre-analytical Method | The DNA concentration in the tissue elute was measured in nanogram per microliter (ng/mcL). | Up to 6 months |
| Amount of DNA by Pre-analytical Method | The total DNA concentration extracted from the tissue was measured in nanogram (ng). | Up to 6 months |
| Size of Amplicons Used by "In-house" Analytical Method | The method described the size of amplicon used. It was measured in base pairs (bp). | Up to 6 months |
| Method of Mutation Detection by "In-house" Analytical Method | Allele-specific PCR, High Resolution Melting (HRM) + Sanger sequencing, Pyrosequencing, Sanger sequencing, Real time PCR, SNaPshot were used for BRAF V600 mutation detection. | Up to 6 months |
| Number of Samples Punched in In-house Analytical Method | Total number of samples for whom punch was used in 'in-house analytical' method are reported. | Up to 6 months |
| Mean Number of Slices Per Sample Used for "In-house"- Analytical Method | The mean of number of slices per sample when no punch was used are reported. | Up to 6 months |
| Median Time Between Receipt of Samples and Determination of Result by "In-house" Analytical Method | This In-house analytical method measured the time between receipt of samples to the result determination. It measured the time in days. | Up to 6 months |
| Technician Work Time Between DNA Extraction and Result by "In-house" Analytical Method | The working time required by the technician from the time of DNA extraction to the time to obtain the results was measured in hours. | Up to 6 months |
| Mean DNA Concentration as Measured by COBAS 4800 BRAF V600 Mutation Test-Analytical Method | The DNA concentration as assessed by COBAS 4800 BRAF V600 Mutation assay was reported. The unit used to measure the DNA concentration was nanogram/microlitre (ng/mcl) | Up to 6 months |
| Punch Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method | The punch done during Cobas 4800 BRAF V600 Mutation Test on the sample was described as Yes or No. | Up to 6 months |
| Number of Slices Used When No Punch Was Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method | This describes the Cobas 4800 BRAF V600 Mutation Test, for the mean of number of slices when No punch method, was used. Of the 420 samples, punch was Yes, for 45 samples and punch was No, for 375 samples. | Up to 6 months |
| Median Time Between Receipt of Sample and Determination of Result by Cobas 4800 BRAF V600 Mutation Test -Analytical Method | This analytical method for cobas 4800 BRAF V600 Mutation Test measured the time between receipt of samples to the result determination. It measured the time in days. | Up to 6 months |
| Technician Work Time Between DNA Extraction and Result by Cobas 4800 BRAF V600 Mutation Test - Analytical Method | This cobas 4800 BRAF V600 Mutation Test analytical method measures the working time required by the technician from the time of DNA extraction to the time to obtain the results. The time duration was measured in hours. | Up to 6 months |
| Management of Discordance- Method Used to Manage Discordance | Crossing DNA, DNA from In-House method analysed with cobas, SNaPshot, DNA from cobas analysed with In-House method, external site control test, Sanger sequencing, Kit CE-IVD Therascreen RGQ Qiagen, Kit Therascreen RGQ BRAF + Pyrosequencing by another platform (PF), Pyrosequencing, Mutation detection On Another Block, (primitive tumor [prm. tmr]), Sequencing And Therascreen kit (Qiagen) were used for management of discordance between "in-house" method and Cobas 4800 mutation test. | Up to 6 months |
| Management of Discordance-Final Result for BRAF V600 Mutation Detection | The final results obtained by discordance management of the 28 discordant samples were BRAF V600 mutation, No BRAF V600 mutation and Non-evaluable. These results were further assessed by the Investigator and interpreted as final result. | Up to 6 months |
| Colmar |
| 68024 |
| France |
| Lille | 59037 | France |
| Lyon | 69437 | France |
| Marseille | 13015 | France |
| Montpellier | 34295 | France |
| Nantes | 44093 | France |
| Paris | 75010 | France |
| Pessac | 33604 | France |
| Rouen | 76031 | France |
| Vandœuvre-lès-Nancy | 54511 | France |
| Villejuif | 94505 | France |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Cobas 4800 Mutation Test | BRAF V600 mutations were analysed using Cobas 4800 mutation test |
|
|
|
| Secondary | Tumor Sample Characteristics-Type of Tumor Sample | The type of tumor sample used for evaluation of BRAF V600 mutation whether it was a biopsy or surgical specimen were reported | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Tumor Sample Characteristics - Source of Tumor Sample | The source of tumor sample for BRAF V600 mutation detection whether taken from internal or external pathology laboratory were reported | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Type of Pathology Laboratory Performing the Fixation or Embedding-Pre-analytical Method | The external or internal pathology laboratories involved in the process of fixation or embedding of the tumor sample was evaluated. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Time From Sampling to Fixation- Pre-analytical Method | Time taken from the sampling to the fixation of the tumor sample was reported in range of 0-2 hours, 2-6 hours, >6 hours and unknown. Number of samples falling in each of the class were reported. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Type of Fixative Used- Pre-analytical Method | The different types of fixative Excell, formol, alcohol formol acetic acid and other, used to fix the tumor samples were reported. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Fixation Duration by Pre-analytical Method | Fixation duration is defined as the amount of time required in hours for the fixation of a samples. The fixation duration was categorized as <6 hours, 6-24 hours and >24 hours and unknown. Number of samples falling in each category were reported | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Slice Thickness by Pre-analytical Method | Slice thickness of all the tumour samples was measured. The slice thickness was measured in micrometer. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Mean | Standard Deviation | micrometer (µm) | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Dewaxing by Pre-analytical Method | Dewaxing is a method to recover the DNA from samples. Dewaxing information was collected as "Yes, No or Missing" | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 Months | Tumor Samples | Participants |
|
|
|
| Secondary | Necrosis Percentage Determination by Pre-analytical Method | The percentage of necrosis defined as the death of one or more cells in the analysed zone was reported. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. Only 341 samples out of 420 were analysed as the information on presence of necrosis was missing for 79 samples in the assessed zones. | Posted | Mean | Standard Deviation | percentage | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Percentage of Tumor Cells by Pre-analytical Method | The percentage of tumor cells in the given tumor sample were reported. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Mean | Standard Deviation | percentage | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Tumor Samples With Presence of Melanin by Pre-analytical Method | The tumor samples with presence of melanin were categorized as Important, Few, Medium and Absent. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. Only available samples were included for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | DNA Extraction - Extraction Method by Pre-analytical Method | This method assessed DNA from the tumor samples was extracted by Automated method or Manual method. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Median DNA Elution Volume by Pre-analytical Method | Median DNA elution volume microliters [mcl] was reported. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Median | Full Range | mcl | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Mean DNA Concentration by Pre-analytical Method | The DNA concentration in the tissue elute was measured in nanogram per microliter (ng/mcL). | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Mean | Standard Deviation | ng/mcl | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Amount of DNA by Pre-analytical Method | The total DNA concentration extracted from the tissue was measured in nanogram (ng). | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Mean | Standard Deviation | ng | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Size of Amplicons Used by "In-house" Analytical Method | The method described the size of amplicon used. It was measured in base pairs (bp). | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Median | Full Range | bp | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Method of Mutation Detection by "In-house" Analytical Method | Allele-specific PCR, High Resolution Melting (HRM) + Sanger sequencing, Pyrosequencing, Sanger sequencing, Real time PCR, SNaPshot were used for BRAF V600 mutation detection. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Number of Samples Punched in In-house Analytical Method | Total number of samples for whom punch was used in 'in-house analytical' method are reported. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Mean Number of Slices Per Sample Used for "In-house"- Analytical Method | The mean of number of slices per sample when no punch was used are reported. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. Data for the samples where the punch was not used were considered for analysis. | Posted | Mean | Standard Deviation | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Median Time Between Receipt of Samples and Determination of Result by "In-house" Analytical Method | This In-house analytical method measured the time between receipt of samples to the result determination. It measured the time in days. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Median | Full Range | days | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Technician Work Time Between DNA Extraction and Result by "In-house" Analytical Method | The working time required by the technician from the time of DNA extraction to the time to obtain the results was measured in hours. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Median | Full Range | hours | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Mean DNA Concentration as Measured by COBAS 4800 BRAF V600 Mutation Test-Analytical Method | The DNA concentration as assessed by COBAS 4800 BRAF V600 Mutation assay was reported. The unit used to measure the DNA concentration was nanogram/microlitre (ng/mcl) | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Mean | Standard Deviation | ng/mcl | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Punch Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method | The punch done during Cobas 4800 BRAF V600 Mutation Test on the sample was described as Yes or No. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Number of Slices Used When No Punch Was Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method | This describes the Cobas 4800 BRAF V600 Mutation Test, for the mean of number of slices when No punch method, was used. Of the 420 samples, punch was Yes, for 45 samples and punch was No, for 375 samples. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. Data for the samples where the punch was No=375, was used for analysis. | Posted | Mean | Standard Deviation | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Median Time Between Receipt of Sample and Determination of Result by Cobas 4800 BRAF V600 Mutation Test -Analytical Method | This analytical method for cobas 4800 BRAF V600 Mutation Test measured the time between receipt of samples to the result determination. It measured the time in days. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Median | Full Range | days | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Technician Work Time Between DNA Extraction and Result by Cobas 4800 BRAF V600 Mutation Test - Analytical Method | This cobas 4800 BRAF V600 Mutation Test analytical method measures the working time required by the technician from the time of DNA extraction to the time to obtain the results. The time duration was measured in hours. | All samples meeting the inclusion criteria and not meeting the exclusion criteria were considered for analysis. | Posted | Median | Full Range | hours | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Management of Discordance- Method Used to Manage Discordance | Crossing DNA, DNA from In-House method analysed with cobas, SNaPshot, DNA from cobas analysed with In-House method, external site control test, Sanger sequencing, Kit CE-IVD Therascreen RGQ Qiagen, Kit Therascreen RGQ BRAF + Pyrosequencing by another platform (PF), Pyrosequencing, Mutation detection On Another Block, (primitive tumor [prm. tmr]), Sequencing And Therascreen kit (Qiagen) were used for management of discordance between "in-house" method and Cobas 4800 mutation test. | The discordant sample population is defined as the samples whose result for BRAF V600 mutation by the "in-house" method did not show similar outcome with the cobas 4800 mutation test. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| Secondary | Management of Discordance-Final Result for BRAF V600 Mutation Detection | The final results obtained by discordance management of the 28 discordant samples were BRAF V600 mutation, No BRAF V600 mutation and Non-evaluable. These results were further assessed by the Investigator and interpreted as final result. | The discordant sample population is defined as the samples whose result for BRAF V600 mutation by the "in-house" method did not show similar outcome with the cobas 4800 mutation test. | Posted | Number | number of samples | Up to 6 months | Tumor Samples | Participants |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Cobas 4800 Mutation Test | BRAF V600 mutations were analysed using Cobas 4800 mutation test | 0 | 0 | 0 | 0 |
The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| Title | Measurements |
|---|---|
|
| Unknown |
|
| Title | Measurements |
|---|---|
|
| Other |
|
| Title | Measurements |
|---|---|
|
| Unknown |
|
| Title | Measurements |
|---|
|
| Title | Measurements |
|---|
|
| Absent |
|
| Title | Measurements |
|---|---|
|
| Real time PCR |
|
| SNaPshot |
|
| Sanger sequencing |
|
| Title | Measurements |
|---|---|
|
| DNA from cobas analysed with In-House method |
|
| External site control test |
|
| Sanger sequencing |
|
| Kit CE-IVD Therascreen RGQ Qiagen |
|
| KIT THERASCREEN RGQ BRAF+PYROSEQ. by other PF |
|
| Pyrosequencing |
|
| Mutation detection on other Block, (prm. tmr) |
|
| Sequencing and Therascreen kit (Qiagen) |
|
| Title | Measurements |
|---|---|
|